Prof Robert Bristow

University Professor of Cancer Studies, Director of MCRC

Full contact details
View graph of relations

Overview

MD (Toronto, 1992), PhD (Medical Biophysics, Toronto, 1997) FRCPC

 

University Professor of Cancer Studies, The University of Manchester

Director, Manchester Cancer Research Centre

Chief Academic Officer, The Christie NHS Foundation Trust

Senior Group Leader, Cancer Research UK Manchester Institute

 

Biography

Robert Bristow MD PhD FRCPC is University Professor of Cancer Studies in the Division of Cancer Sciences (The University of Manchester) and Chief Academic Officer at The Christie NHS Foundation Trust.  

He was previously a Clinician-Scientist and Professor within the Departments of Radiation Oncology and Medical Biophysics at the University of Toronto and a Senior Scientist at the Princess Margaret Cancer Centre.

His primary research interests are in tumour hypoxia, DNA damage signalling and DNA repair in tumours, and the genomics of prostate cancer progression and cancer treatment response. He is particularly interested in novel clinical trials that intensify cancer therapy to prostate cancer patients whose tumours harbour aggressive genetic changes and hypoxic sub-regions. 

 

Key Publications

Mitochondrial mutations drive prostate cancer aggression.
Hopkins JF, Sabelnykova VY, Weischenfeldt J, Simon R, Aguiar JA, Alkallas R, Heisler LE, Zhang J, Watson JD, Chua MLK, Fraser M, Favero F, Lawerenz C, Plass C, Sauter G, McPherson JD, van der Kwast T, Korbel J, Schlomm T, Bristow RG, Boutros PC.
Nat Commun. (2017) 8(1):656. doi: 10.1038/s41467-017-00377-y.
 
TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer.
Kron KJ, Murison A, Zhou S, Huang V, Yamaguchi TN, Shiah YJ, Fraser M, van der Kwast T, Boutros PC, Bristow RG, Lupien M.
Nat Genet. (2017) 49(9):1336-1345. doi: 10.1038/ng.3930. 
 
A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.
Chua MLK, Lo W, Pintilie M, Murgic J, Lalonde E, Bhandari V, Mahamud O, Gopalan A, Kweldam CF, van Leenders GJLH, Verhoef EI, Hoogland AM, Livingstone J, Berlin A, Dal Pra A, Meng A, Zhang J, Orain M, Picard V, Hovington H, Bergeron A, Lacombe L, Fradet Y, Têtu B, Reuter VE, Fleshner N, Fraser M, Boutros PC, van der Kwast TH, Bristow RG.
Eur Urol. (2017) 72(5):665-674. doi: 10.1016/j.eururo.2017.04.034. 
 
Intraductal Carcinoma of the Prostate: Anonymous to Ominous.
Chua MLK, van der Kwast TH, Bristow RG.
Eur Urol. (2017) 72(4):496-498. doi: 10.1016/j.eururo.2017.04.004. 
 
The Evolving Narrative of DNA Repair Gene Defects: Distinguishing Indolent from Lethal Prostate Cancer.
Murphy DG, Risbridger GP, Bristow RG, Sandhu S.
Eur Urol. (2017) 71(5):748-749. doi: 10.1016/j.eururo.2017.01.025. 
 
Genomic hallmarks of localized, non-indolent prostate cancer.
Fraser M, Sabelnykova VY, Yamaguchi TN, Heisler LE, Livingstone J, Huang V, Shiah YJ, Yousif F, Lin X, Masella AP, Fox NS, Xie M, Prokopec SD, Berlin A, Lalonde E, Ahmed M, Trudel D, Luo X, Beck TA, Meng A, Zhang J, D'Costa A, Denroche RE, Kong H, Espiritu SM, Chua ML, Wong A, Chong T, Sam M, Johns J, Timms L, Buchner NB, Orain M, Picard V, Hovington H, Murison A, Kron K, Harding NJ, P'ng C, Houlahan KE, Chu KC, Lo B, Nguyen F, Li CH, Sun RX, de Borja R, Cooper CI, Hopkins JF, Govind SK, Fung C, Waggott D, Green J, Haider S, Chan-Seng-Yue MA, Jung E, Wang Z, Bergeron A, Dal Pra A, Lacombe L, Collins CC, Sahinalp C, Lupien M, Fleshner NE, He HH, Fradet Y, Tetu B, van der Kwast T, McPherson JD, Bristow RG, Boutros PC.
Nature. (2017) 541(7637):359-364. doi: 10.1038/nature20788. 
 
Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.
Taylor RA, Fraser M, Livingstone J, Espiritu SM, Thorne H, Huang V, Lo W, Shiah YJ, Yamaguchi TN, Sliwinski A, Horsburgh S, Meng A, Heisler LE, Yu N, Yousif F, Papargiris M, Lawrence MG, Timms L, Murphy DG, Frydenberg M, Hopkins JF, Bolton D, Clouston D, McPherson JD, van der Kwast T, Boutros PC, Risbridger GP, Bristow RG.
Nat Commun. (2017) Jan 9;8:13671. doi: 10.1038/ncomms13671.
 
Testosterone in Androgen Receptor Signaling and DNA Repair: Enemy or Frenemy?
Chua ML, Bristow RG.
Clin Cancer Res. (2016) 22(13):3124-6. doi: 10.1158/1078-0432.CCR-16-0381. 
 
In vivo studies of the PARP inhibitor, AZD-2281, in combination with fractionated radiotherapy: An exploration of the therapeutic ratio.
Gani C, Coackley C, Kumareswaran R, Schütze C, Krause M, Zafarana G, Bristow RG.
Radiother Oncol. (2015) 116(3):486-94. doi: 10.1016/j.radonc.2015.08.003. 
 
Spatial genomic heterogeneity within localized, multifocal prostate cancer.
Boutros PC, Fraser M, Harding NJ, de Borja R, Trudel D, Lalonde E, Meng A, Hennings-Yeomans PH, McPherson A, Sabelnykova VY, Zia A, Fox NS, Livingstone J, Shiah YJ, Wang J, Beck TA, Have CL, Chong T, Sam M, Johns J, Timms L, Buchner N, Wong A, Watson JD, Simmons TT, P'ng C, Zafarana G, Nguyen F, Luo X, Chu KC, Prokopec SD, Sykes J, Dal Pra A, Berlin A, Brown A, Chan-Seng-Yue MA, Yousif F, Denroche RE, Chong LC, Chen GM, Jung E, Fung C, Starmans MH, Chen H, Govind SK, Hawley J, D'Costa A, Pintilie M, Waggott D, Hach F, Lambin P, Muthuswamy LB, Cooper C, Eeles R, Neal D, Tetu B, Sahinalp C, Stein LD, Fleshner N, Shah SP, Collins CC, Hudson TJ, McPherson JD, van der Kwast T, Bristow RG.
Nat Genet. (2015) 47(7):736-45. doi: 10.1038/ng.3315. 
 
Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study.
Lalonde E, Ishkanian AS, Sykes J, Fraser M, Ross-Adams H, Erho N, Dunning MJ, Halim S, Lamb AD, Moon NC, Zafarana G, Warren AY, Meng X, Thoms J, Grzadkowski MR, Berlin A, Have CL, Ramnarine VR, Yao CQ, Malloff CA, Lam LL, Xie H, Harding NJ, Mak DY, Chu KC, Chong LC, Sendorek DH, P'ng C, Collins CC, Squire JA, Jurisica I, Cooper C, Eeles R, Pintilie M, Dal Pra A, Davicioni E, Lam WL, Milosevic M, Neal DE, van der Kwast T, Boutros PC, Bristow RG.
Lancet Oncol. (2014) Dec;15(13):1521-32. doi: 10.1016/S1470-2045(14)71021-6. 
 

Qualifications

FRCPC

MD

PhD

Research Networks and Beacons

Biology, Medicine and Health (BMH) Domains

Related information